儿童播散性低级别胶质瘤的整合临床与分子特征
该国际多中心队列纳入269例播散性儿童型低级别胶质瘤患者,结合DNA测序与甲基化谱分析进行临床和分子特征刻画。研究按播散的时间与空间分布识别出三个亚组,其中无原发肿瘤块的弥漫性软脑膜播散及婴儿患者预后最差。靶向RAS/MAPK通路抑制作为一线或二线治疗优于传统化疗。
要点
- 播散性PLGG可按时间与空间分布分为三个亚组。
- 无原发肿块弥漫软脑膜播散及婴儿患者结局最差。
- 靶向RAS/MAPK通路抑制作为一/二线治疗优于传统化疗。
核心结论
- 播散性PLGG的遗传学特征与非播散性PLGG高度重叠,提示非遗传机制是播散的重要Contributor。
- 靶向RAS/MAPK通路抑制作为一线或二线治疗比传统化疗更有效。
研究设计与样本
- 国际多中心队列研究,纳入269例播散性PLGG患者。
- 对患者进行详细临床与分子特征刻画,包括DNA测序和甲基化谱分析。
主要发现
- 基于播散的时间与空间分布识别出三个患者亚组。
- 无原发肿瘤块的弥漫性软脑膜播散及婴儿患者临床结局最差。
- 播散性PLGG的遗传学改变与非播散性PLGG高度重叠。
临床怎么用
- 对播散性PLGG可按播散时空分布进行亚组分层以评估预后。
- 无原发肿块弥漫软脑膜播散及婴儿患者需重点关注。
- 一线或二线治疗可优先考虑靶向RAS/MAPK通路抑制而非传统化疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT: BackgroundPediatric-type low-grade gliomas (PLGG) are the most common central nervous system (CNS) tumor in children. Many are indolent and have excellent outcomes; however, some inexplicably spread throughout the CNS leading to increased morbidity and mortality. METHODS: To better understand this rare and difficult-to-treat entity, as well as the features associated with dissemination in CNS tumors, we assembled a large international cohort (n = 269) of patients with disseminated PLGG with detailed clinical and molecular characterization, including DNA sequencing and methylome profiling. RESULTS: We identified three subgroups of patients based on the temporal and spatial distribution of dissemination. Tumors with diffuse leptomeningeal spread without a primary tumor mass and those occurring in infants had the worst clinical outcomes. The genetics overlapped substantially with that of non-disseminated PLGG, suggesting that non-genetic mechanisms are an important contributor to dissemination. Therapeutically, targeted RAS/MAPK-pathway inhibition was more effective than conventional chemotherapy as first or second-line treatment. CONCLUSIONS: In sum, this cohort increases our clinical and biological understanding of this rare disease, provides insights for improving patient care, and directs future clinical trials and basic science research.
引用
- Levine AB, Bennett J, Patil P, et al. Integrated clinical and molecular landscape of disseminated pediatric low-grade glioma. Neuro Oncol. 2026. PMID: 41117845. doi:10.1093/neuonc/noaf245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。